Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
Custom Award recognizing contributions to the development of a medical implant, and embedding the actual device within Lucite. (23AZH106)
Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Crystal financial tombstone commemorating a public offering of common stock by Kiora Pharmaceuticals. The California-based biotech company concentrates on developing and commercializing treatments for rare retinal diseases. (23AJH059)
Crystal financial tombstone commemorating a follow-on offering of stock by Intelligent Bio Solutions. The New York-based life sciences company develops non-invasive monitoring and diagnostic tests. (23AKL447)
Financial tombstone, featuring a hospital building replica in crystal, celebrating the successful placment of “green” bonds by the Insel Group. The hospital network is based in Switzerland. (23LNL167)
